ICICI Securities's research report on Honasa Consumer
Honasa’s Q2FY26 performance reaffirms its focus on building category depth, scaling younger brands, and strengthening distribution reach. Mamaearth is back to growth (LFL: double digit) and sustained traction across younger brands such as The Derma Co. underscoring portfolio resilience, while continued innovation and selective entry into premium segments strengthened category relevance. Expanding offline footprint, improving mix and disciplined cost control supported steady margin progression in Q2. With younger brands now contributing >50% of revenue, new initiatives such as Luminéve in premium skincare and Fang in oral care broaden Honasa’s play in emerging adjacencies. The business enters H2FY26 on a steady footing, with margin tailwinds and broad-based brand momentum likely to drive healthy performance ahead. BUY.
Outlook
Maintain BUY with DCF-based target price of INR 400 as we roll forward to Sep’27E. At our TP, the stock could trade at 59x Sep’27E EPS. Key risks: 1) Heightened competition, 2) execution miss, 3) low success in scale-up of new brands and 4) continued slowdown in Mamaearth.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.